UK pharma group, Croda International, has inked a deal with the US government in which it will receive up to US$75m to expand its US manufacturing capacity for lipid systems.
Evonik will build a production facility for pharmaceutical lipids in Indiana: with the new site ‘positioning the group for future growth in novel mRNA-based therapies beyond COVID-19 vaccines’.
Lipid nanoparticle systems (LNPs) as a delivery mechanism for novel drug modalities are proving effective, but there are bioanalytical challenges associated with encapsulation, says an expert.
Sweden’s Biotage says its expanded facility in the UK will allow it to triple its production capacity for equipment crucial in the supply chain for the production of mRNA vaccines, and thus eliminating a bottleneck for COVID-19 vaccines.